Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer In­gel­heim has qui­et­ly shut down a small Phase II study for one of its lead drugs.

The pri­vate phar­ma play­er con­firmed to End­points News that it had shut­tered a study test­ing spesolimab as a ther­a­py for Crohn’s pa­tients suf­fer­ing from bow­el ob­struc­tions.

A spokesper­son for the com­pa­ny tells End­points:

Tak­ing in­to con­sid­er­a­tion the cur­rent ther­a­peu­tic land­scape and on­go­ing clin­i­cal de­vel­op­ment pro­grams, Boehringer In­gel­heim de­cid­ed to dis­con­tin­ue our pro­gram in Crohn’s dis­ease. It is im­por­tant to note that this de­ci­sion is not based on any safe­ty find­ings in the clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER